Benign Prostatic Hyperplasia Treatment Market

Benign Prostatic Hyperplasia Treatment Device Treatment Type Insights:

On the basis of treatment type, the global BPH treatment market is segmented into combination drug therapy and mono-drug therapy. Dominance of combination drug therapy segment

In the global market for BPH treatment, the combination drug therapy segment held the largest revenue share in 2022. This treatment reduced side effects, increased effectiveness, enhanced compliance, and lowered costs. When treating patients with mild to moderate lower urinary system symptoms, combination medication therapy is the first line of treatment (LUT). Apart from mitigating symptoms, these therapies also have the potential to stop the disease's progression and avoid complications such as Acute Urine Retention (AUR) or surgeries related to BPH.

Over the course of the forecast period, the global market for BPH treatment is anticipated to witness a consistently rapid revenue growth rate in the mono drug therapy segment. Clinical trials have shown that in men receiving alpha-blocker monotherapy but still experiencing bothersome storage LUTS, adding an OAB medication significantly reduces storage symptoms and improves quality of life. When alpha-blocker monotherapy is ineffective in relieving storage symptoms, clinical guidelines recommend incorporating a beta-3 agonist or antimuscarinic medication into the treatment regimen. Tamsulosin monotherapy was the most often prescribed treatment for sub-cohort patients (58.3%), followed by doxazosin.

Benign Prostatic Hyperplasia Treatment Device Therapy Type Insights: On the basis of therapy type, the global BPH treatment market is segmented into drug type and minimally invasive surgeries, laser therapy, and others. Dominance of drug type segment

Over the course of the forecast period, the drug type segment is anticipated to hold a sizable revenue share in the global BPH treatment market.  This is due to the fact that certain alpha blockers, such as terazosin (Hytrin), doxazosin (Cardura), alfuzosin (Uroxatral), and tamsulosin (Flomax), can relax the muscles in the prostate and the neck of the bladder. However, 5-alpha reductase inhibitors (5-ARIs) effectively reduce blood and prostate DHT levels, which results in the involution of prostate tissue.

Right now, there are two 5-ARIs used to treat BPH: finasteride and dutasteride. Both have been demonstrated to improve LUTS, decrease prostate volume, and raise urine flow rates, all of which reduce the chance that surgery related to BPH and AUR will be required. Aside from that, BPH and hypertension are common in aging men. As the world's population ages, these two diseases are developing into significant global public health concerns. Thirty percent of men undergoing BPH treatment also suffer from hypertension. In addition, e-beta-adrenergic blockers (Prazosin, Terazosin, and Doxazosin) are effective BPH medications and well-known treatments for hypertension.

[caption id="attachment_9369" align="alignleft" width="680"] Benign Prostatic Hyperplasia Treatment Market | Exactitude Consultancy[/caption]

Benign Prostatic Hyperplasia Treatment Market Players

The key players operating in the global benign prostatic hyperplasia therapeutics market are Abbott Laboratories, AbbVie (Allergan Plc), Astellas Pharma Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Eli Lilly and Company, GlaxoSmithKline plc., Merck & Co., Inc. (Merck Sharp & Dohme Corp), Pfizer Inc., Sanofi and Teva Pharmaceutical Industries Limited.

Recent Development:

• Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products.
• AbbVie focuses on discovering and delivering transformational medicines and products in several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, and women's health, as well as through their Allergan Aesthetics portfolio.
• Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd.

Who Should Buy? Or Key Stakeholders

• Plastic Industry
• Chemical Industry
• Construction Industry
• Scientific Research and Development
• Investors
• Manufacturing companies
• End user companies
• Others

Key Takeaways:

• Benign prostatic hyperplasia treatment market is projected to be growing at a CAGR of 19.4%
• Based on treatment, the largest and fastest-growing segment of this industry is drug treatment.
• Based on end-user, home healthcare accounted for the greatest share of this market.
• The market for benign prostatic hyperplasia treatment was dominated by North America.
• Combination therapies emerging as a prominent trend in the benign prostatic hyperplasia treatment market.

Benign Prostatic Hyperplasia Treatment Market Regional Analysis

The global benign prostatic hyperplasia market by region includes North America, Asia-Pacific (APAC), Europe, South America, and Middle East & Africa (MEA).

• North America: includes the US, Canada, Mexico
• Asia Pacific: includes China, Japan, South Korea, India, Australia, ASEAN and Rest of APAC
• Europe: includes UK, Germany, France, Italy, Spain, Russia, and Rest of Europe
• South America: includes Brazil, Argentina and Rest of South America
• Middle East & Africa: includes Turkey, UAE, Saudi Arabia, South Africa, and Rest of MEA

The market for benign prostatic hyperplasia treatment was dominated by North America. The expanding elderly and obese population, as well as the availability of research funding, are the primary factors driving market expansion. Key players' initiatives are also expected to have an impact on the industry.

[caption id="attachment_9370" align="alignleft" width="680"] Benign Prostatic Hyperplasia Treatment Market | Exactitude Consultancy[/caption]

Key Market Segments: Benign Prostatic Hyperplasia Treatment Market

Benign Prostatic Hyperplasia Treatment Market by Treatment, 2020-2029, (USD Million)

• Drug Class
• Minimally Invasive Surgeries
• Laser Therapy

Benign Prostatic Hyperplasia Treatment Market by End User, 2020-2029, (USD Million)

• Hospitals
• Ambulatory Surgical Centres
• Specialty Clinics

Benign Prostatic Hyperplasia Treatment Market by Region, 2020-2029, (USD Million)

• North America
• Europe
• Asia Pacific
• South America
• Middle East And Africa

Important countries in all regions are covered

Key Question Answered

• What are the growth opportunities related to the adoption of benign prostatic hyperplasia treatment across major regions in the future?
• What are the new trends and advancements in the benign prostatic hyperplasia treatment market?

• Which product categories are expected to have highest growth rate in the benign prostatic hyperplasia treatment market?

• Which are the key factors driving the benign prostatic hyperplasia treatment market?
• What will the market growth rate, growth momentum or acceleration the market carries during the forecast period?

1. Introducción
   
   
   
   1. Definición de mercado
   
   
   2. Segmentación del mercado
   
   
   3. Cronología de la investigación
   
   
   4. Supuestos y limitaciones
   
   
   
   


2. Metodología de la investigación
   
   
   
   1. Minería de datos
      
      
      
      1. Investigación secundaria
      
      
      2. Investigación primaria
      
      
      3. Asesoramiento de expertos en la materia
      
      
      
      
   
   
   2. Controles de calidad
      
      
      
      1. Revisión final
      
      
      
      
   
   
   3. Triangulación de datos
      
      
      
      1. Enfoque de abajo hacia arriba
      
      
      2. Enfoque de arriba hacia abajo
      
      
      3. Flujo de investigación
      
      
      
      
   
   
   4. Fuentes de datos
   
   
   
   


3. Resumen ejecutivo


4. Descripción general del mercado
   
   
   
   1. Perspectivas del mercado mundial de tratamiento de la hiperplasia prostática benigna
      
      
      
      1. Factores impulsores del mercado
      
      
      2. Restricciones del mercado
      
      
      3. Oportunidades de mercado
      
      
      
      
   
   
   2. Impacto de Covid-19 en el mercado de tratamiento de la hiperplasia prostática benigna
   
   
   3. Modelo de las cinco fuerzas de Porter
      
      
      
      1. Amenaza de nuevos participantes
      
      
      2. Amenaza de sustitutos
      
      
      3. Poder de negociación de los proveedores
      
      
      4. Poder de negociación de los clientes
      
      
      5. Grado de competencia
      
      
      
      
   
   
   4. Análisis de la cadena de valor de la industria
   
   
   
   


5. Mercado mundial de tratamiento de la hiperplasia prostática benigna por tratamiento (millones de USD)
   
   
   
   1. Clase de droga
   
   
   2. Cirugías mínimamente invasivas
   
   
   3. Terapia con láser
   
   
   
   


6. Mercado mundial de tratamiento de la hiperplasia prostática benigna por usuario final (millones de USD)
   
   
   
   1. Hospitales
   
   
   2. Centros de cirugía ambulatoria
   
   
   3. Clínicas de especialidades
   
   
   
   


7. Mercado mundial de tratamiento de la hiperplasia prostática benigna por región (millones de USD)
   
   
   
   1. América del norte
      
      
      
      1. A NOSOTROS
      
      
      2. Canadá
      
      
      3. México
      
      
      
      
   
   
   2. Sudamerica
      
      
      
      1. Brasil
      
      
      2. Argentina
      
      
      3. Colombia
      
      
      4. Resto de Sudamérica
      
      
      
      
   
   
   3. Europa
      
      
      
      1. Alemania
      
      
      2. Reino Unido
      
      
      3. Francia
      
      
      4. Italia
      
      
      5. España
      
      
      6. Rusia
      
      
      7. Resto de Europa
      
      
      
      
   
   
   4. Asia Pacífico
      
      
      
      1. India
      
      
      2. Porcelana
      
      
      3. Japón
      
      
      4. Corea del Sur
      
      
      5. Australia
      
      
      6. Sudeste asiático
      
      
      7. Resto de Asia Pacífico
      
      
      
      
   
   
   5. Oriente Medio y África
      
      
      
      1. Emiratos Árabes Unidos
      
      
      2. Arabia Saudita
      
      
      3. Sudáfrica
      
      
      4. Resto de Oriente Medio y África
      
      
      
      
   
   
   
   


8. Perfiles de empresas* (descripción general de la empresa, descripción general de la empresa, productos ofrecidos, desarrollos recientes)


9. 
   
   
   
   1. Laboratorios Abbott
   
   
   2. AbbVie (Allergan Plc)
   
   
   3. Compañía farmacéutica Astellas Inc.
   
   
   4. Boehringer Ingelheim Pharma GmbH & Co. KG
   
   
   5. Eli Lilly y compañía
   
   
   6. Compañía: GlaxoSmithKline plc.
   
   
   7. Merck & Co., Inc. (Merck Sharp & Dohme Corp)
   
   
   8. Pfizer Inc.
   
   
   9. Sanofi
   
   
   10. Industrias farmacéuticas Teva limitada
   
   
   
   

*The Company List Is Indicative

 

LIST OF TABLES

TABLE 1                GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 2                GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 3                GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY REGION (USD MILLIONS) 2020-2029

TABLE 4                US BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 5                US BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 6                CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 7                CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 8                MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 9                MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 10              BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 11              BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 12              ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 13              ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 14              COLOMBIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 15              COLOMBIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 16              REST OF SOUTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 17              REST OF SOUTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 18              INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 19              INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 20              CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 21              CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 22              JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 23              JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 24              SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 25              SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 26              AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 27              AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 28              SOUTH-EAST ASIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 29              SOUTH-EAST ASIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 30              REST OF ASIA PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 31              REST OF ASIA PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 32              GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 33              GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 34              UK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 35              UK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 36              FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 37              FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 38              ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 39              ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 40              SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 41              SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 42              RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 43              RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 44              REST OF EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 45              REST OF EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 46              UAE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 47              UAE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 48              SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 49              SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 50              SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 51              SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

TABLE 52              REST OF MIDDLE EAST AND AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT (USD MILLIONS) 2020-2029

TABLE 53              REST OF MIDDLE EAST AND AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER (USD MILLIONS) 2020-2029

 

 

LIST OF FIGURES

FIGURE 1        MARKET DYNAMICS

FIGURE 2        MARKET SEGMENTATION

FIGURE 3        REPORT TIMELINES: YEARS CONSIDERED

FIGURE 4        DATA TRIANGULATION

FIGURE 5        BOTTOM-UP APPROACH

FIGURE 6        TOP-DOWN APPROACH

FIGURE 7        RESEARCH FLOW

FIGURE 8        GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY TREATMENT, USD MILLION, 2020-2029

FIGURE 9        GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER, USD MILLION, 2020-2029

FIGURE 10     GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY END USER, USD MILLION, 2020-2029

FIGURE 11     GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET BY REGION, USD MILLION, 2020-2029

FIGURE 12     PORTER’S FIVE FORCES MODEL

FIGURE 13     NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SNAPSHOT

FIGURE 14     EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SNAPSHOT

FIGURE 15     ASIA PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SNAPSHOT

FIGURE 16     SOUTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SNAPSHOT

FIGURE 17     MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SNAPSHOT

FIGURE 18     ABBOTT LABORATORIES: COMPANY SNAPSHOT

FIGURE 19     ABBVIE (ALLERGAN PLC): COMPANY SNAPSHOT

FIGURE 20     ASTELLAS PHARMA INC.: COMPANY SNAPSHOT

FIGURE 21     BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG: COMPANY SNAPSHOT

FIGURE 22     ELI LILLY AND COMPANY: COMPANY SNAPSHOT

FIGURE 23     GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT

FIGURE 24     MERCK & CO., INC. (MERCK SHARP & DOHME CORP): COMPANY SNAPSHOT

FIGURE 25     PFIZER INC.: COMPANY SNAPSHOT

FIGURE 26     SANOFI: COMPANY SNAPSHOT

FIGURE 27     TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT